• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Enhanced Anti-influenza Agents Conjugated with Anti-inflammatory Activity

tetano

Editor, Senior Moderator
Jim-Min Fang , Kung-Cheng Liu , Jia-Tsrong Jan , Ting-Jen R. Cheng , Shi-Yun Wang , Shi-Ting Yang , Yih-Shyun E. Cheng , and Chi-Huey Wong
J. Med. Chem., Just Accepted Manuscript
DOI: 10.1021/jm3009844
Publication Date (Web): September 10, 2012
Copyright ? 2012 American Chemical Society
Abstract

Influenza therapy with a single targeted compound is often limited in efficacy due to the rapidly developed drug-resistance. Moreover, the uncontrolled virus-induced cytokines could cause the high mortality of human infected by H5N1 avian influenza virus. In this study, we explored the novel dual-targeted bifunctional anti-influenza drugs formed by conjugation with anti-inflammatory agents. In particular, the caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1) and ZA-7-CA-amide (7) showed simultaneous inhibition of influenza virus neuraminidase and suppression of pro-inflammatory cytokines. These ZA conjugates provided remarkable protection of cells and mice against influenza infections. Intranasal administration of low dosage (<1.2 μmol/kg/day) of ZA conjugates exhibited much greater effect than the combination therapy with ZA and the anti-inflammatory agents in protection of the lethally infected mice by H1N1 or H5N1 influenza viruses.


http://pubs.acs.org/doi/abs/10.1021/jm3009844
 
Back
Top Bottom